Genexine, Inc.
Developing long-acting immunotherapeutics for immuno-oncology and rare diseases.
095700 | KO
Overview
Corporate Details
- ISIN(s):
- KR7095700001
- LEI:
- Country:
- South Korea
- Address:
- 서울특별시 강서구 마곡중앙로 172 바이오이노베이션파크, 강서구
- Website:
- http://www.genexine.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Genexine, Inc. is a clinical-stage biopharmaceutical company focused on the research and development of innovative immunotherapeutics and next-generation biologics. The company leverages its proprietary hyFc® platform technology to create long-acting treatments. Its primary focus areas are immuno-oncology and rare diseases. Key pipeline assets include GX-I7, a long-acting interleukin-7 designed to amplify T-cell counts for cancer therapy, as well as late-stage candidates GX-E4 for anemia and GX-H9 for growth hormone deficiency. Genexine aims to develop novel and "bio-better" drugs to address serious health issues and improve patient outcomes.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-08-20 00:00 |
Regulatory News Service
투자판단관련주요경영사항 (GXI7 관련 마일스톤 기술료 청구)
|
Korean | 7.1 KB | ||
| 2025-08-14 00:00 |
Interim Report
반기보고서 (2025.06)
|
Korean | 1.3 MB | ||
| 2025-05-14 00:00 |
Quarterly Report
분기보고서 (2025.03)
|
Korean | 1.3 MB | ||
| 2025-03-26 00:00 |
Post-Annual General Meeting Information
정기주주총회결과
|
Korean | 29.4 KB | ||
| 2025-03-26 00:00 |
Share Issue/Capital Change
주식매수선택권부여에관한신고
|
Korean | 16.5 KB | ||
| 2025-03-26 00:00 |
Board/Management Information
사외이사의선임ㆍ해임또는중도퇴임에관한신고
|
Korean | 13.9 KB | ||
| 2025-03-26 00:00 |
Board/Management Information
대표이사변경
|
Korean | 10.5 KB | ||
| 2025-03-10 00:00 |
Pre-Annual General Meeting Information
주주총회소집결의
|
Korean | 18.0 KB | ||
| 2025-03-10 00:00 |
Share Issue/Capital Change
주식매수선택권부여에관한신고
|
Korean | 17.2 KB | ||
| 2025-03-10 00:00 |
Pre-Annual General Meeting Information
주주총회소집공고
|
Korean | 152.9 KB | ||
| 2025-03-10 00:00 |
Proxy Solicitation & Information Statement
의결권대리행사권유참고서류
|
Korean | 133.5 KB | ||
| 2025-03-10 00:00 |
Audit Report / Information
감사보고서제출
|
Korean | 19.5 KB | ||
| 2025-03-10 00:00 |
Audit Report / Information
사업보고서 (2024.12)
|
Korean | 618.9 KB | ||
| 2025-02-26 00:00 |
Legal Proceedings Report
투자판단관련주요경영사항(임상시험결과) (재발성 교모세포종 환자에서 베바시주맙 (bevacizumab)과 GX-I7 병용…
|
Korean | 14.1 KB | ||
| 2025-02-06 00:00 |
Earnings Release
매출액또는손익구조30%(대규모법인은15%)이상변동
|
Korean | 11.5 KB |
Automate Your Workflow. Get a real-time feed of all Genexine, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Genexine, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Genexine, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
